Pfizer Ltd schedules board meeting on July 28 to approve Q2 FY2026 unaudited results
The company will hold its board on 28 July 2026 to consider and take on record the unaudited financial results for the quarter ended 30 June 2026.
What Pfizer Ltd announced
Pfizer Ltd informed the Bombay Stock Exchange that its Board of Directors will convene on 28 July 2026 (Tuesday). The sole purpose of the meeting, as per the filing, is to consider, approve and take on record the unaudited financial results for the quarter ended 30 June 2026. No other agenda items were mentioned.
Pfizer Ltd will consider its unaudited Q2 FY2026 results on 28 July 2026.
The notice was submitted to BSE on 20 July 2026 and references the company's BSE ticker 500680. No details of the financial performance – such as revenue, profit, or earnings per share – were included in the filing.
Board meeting agenda
The filing lists the following items under the meeting agenda:
- Consideration of unaudited financial results for the quarter ended 30 June 2026.
- Approval of those results by the Board.
- Taking the results on record as part of the statutory compliance process.
The board’s approval is a prerequisite under Indian corporate law before the company can publicly disclose its quarterly performance. The meeting is expected to be held at the company’s registered office, though the exact venue and time were not disclosed.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Pfizer Ltd |
| BSE ticker | 500680 |
| Filing date | 20 July 2026 (BSE) |
| Board meeting date | 28 July 2026 (Tuesday) |
| Purpose of meeting | Approve unaudited Q2 FY2026 results |
| Quarter covered | 1 July – 30 June 2026 (Q2 FY2026) |
| Financial figures disclosed? | No |
| Source | BSE corporate filing (PDF) |
Why this matters for investors
The board’s approval of unaudited results is a routine but essential step in the quarterly reporting cycle. Once approved, Pfizer Ltd will file the results with the stock exchanges and publish them on its investor‑relations portal. Investors rely on this information to assess the company’s short‑term performance and to compare against analyst expectations. Because the filing contains no quantitative data, investors cannot yet gauge the quarter’s profitability, revenue growth, or margin trends. The announcement therefore signals an upcoming information release rather than an immediate change to the company’s capital structure or operations.
Conclusion
Pfizer Ltd’s board is scheduled to meet on 28 July 2026 to approve the unaudited financial results for the quarter ended 30 June 2026. The filing does not provide any financial numbers, and the results will become publicly available only after the board’s approval. Stakeholders should watch for the subsequent exchange filing that will contain the detailed quarterly figures.
Frequently asked questions
Related stocks
Source filing: view original